Neuroendocrine tumors therapeuticss market Size 2013-2017 | Forecast 2018-2024
Neuroendocrine tumors therapeuticss market Size 2013-2017 | Forecast 2018-2024
Neuroendocrine tumors (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumors are rare and can occur anywhere in the body. Most neuroendocrine tumors occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumors can be noncancerous (benign) or cancerous (malignant). NETs will arises from several neuroendocrine cells whose normal functions are to serve at neuroendocrine interface. Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands.
Neuroendocrine tumors therapeutics market expected to grow owing to increase in initiatives taken by various international organizations like American Association for Cancer Research (AACR) and World Health Organization to treat neuroendocrine tumors are expected to drive the growth of the market. AACR provided $250,000 fund for the prevention of neuro endocrine tumors. Rise in health care expenditure, increase in prevalence rate of neuroendocrine tumors in developing regions is anticipated to drive global neuroendocrine tumors market. Though the market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restraints for neuroendocrine tumors market.
Free sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-neuroendocrine-tumours-therapeutics-market/#ulp-4H8Z4LpNMLEuOnnx
The global Neuro-endocrine tumors therapeutics market is categorized as below-
1. Drug class
• Somatostatin Analogues
o Octreotide
o Lanreotide
o Pasireotide
• Chemotherapeutics
o Fluorouracil (5-FU)
o Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
o Streptozocin
o Temozolomide (Temodar)
o Capecitabine (Xeloda)
o Dacarbazine (DTIC)
o Oxaliplatin (Eloxatin)
• Targeted Therapeutics
o Sunitinib
o Everolimus
• Others
2. Indication
• Lung NET
• Others NET
• Gastrointestinal NET
• Pancreatic NET
3. End-users
Hospital, retail pharmacies and others.
Free TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-neuroendocrine-tumours-therapeutics-market/#ulp-c654SbFYO64MsOhu
And based on the geographical regions, the global neuroendocrine tumors therapeutics market is divided into five key regions- North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa. According to Cancer.Net, approximately 8,000 people are identified with Neuro-endocrine cancer every year in the U.S. Several key players functioning in neuroendocrine tumors therapeutics market are based in the U.S. Hence, in North America became main market for product launch and research and development activities. Furthermore, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine tumors therapeutics market. Europe is the second largest market for neuroendocrine tumors therapeutics, followed by Asia-Pacific. Increase in prevalence of neuroendocrine cancer in Asia-Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region. Some of the key players operating in the global neuroendocrine tumors therapeutics market include Pfizer Inc., (U.S), Eli Lilly & Company (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd.(Switzerland), Ipsen (France), Amgen, Inc. (U.S.), Teva Pharmaceuticals, Ltd. (Israel), and Bristol-Myers Squibb (U.S.). In 2016, Novartis received the USFDA approval for its Afinitor® (Everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin. While in 2014, Ipsen Biopharmaceuticals, Inc., received USFDA approval for Somatuline® Depot® (Lanreotide) injection 120 mg to treat gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients.
Ask Analyst for Full Information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-neuroendocrine-tumours-therapeutics-market/#ulp-14mlyhjMGhVjZqa3
The neuroendocrine tumor treatment market is expected to gain steady traction in the foreseeable future as there are many novel drugs are in pipeline. Increase in NET incidence and prevalence globally. As per the estimation of Canadian Cancer Society (CCS), about 315 individuals were diagnosed with endocrine cancers in 2012 in Canada and rate is raising with early stage diagnosis and migration. Moreover, rise in survival rate of neuroendocrine tumors by treating with various medications are expected to have a positive impact on neuroendocrine tumors market. According to the study published in the JAMA Oncology Journal (2017), the survival rate for all neuroendocrine tumor treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumor treatment and pancreatic neuroendocrine tumor treatment.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-neuroendocrine-tumours-therapeutics-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com